TY - JOUR
T1 - Cytologic Investigations for the Diagnosis of Malignant Pleural Effusion in Non-small Cell Lung Cancer
T2 - State-of-the-art Review for Pulmonologists
AU - Shojaee, Samira
AU - Roy-Chowdhuri, Sinchita
AU - Safi, Javeryah
AU - Grosu, Horiana B.
N1 - Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Lung cancer is the current leading cause of cancer-related deaths worldwide, and malignant pleural effusion, an indicator of the advanced stage of this disease, portends a poor prognosis. Thus, making an accurate diagnosis of malignant pleural effusion is of paramount importance. During the past decade, the prognosis of patients with advanced non-small cell lung cancer has improved substantially, especially in those treated with targeted therapy and immunotherapy. The use of pleural fluid cytology should not only provide diagnoses but also aid in the selection of targeted therapies, especially when obtaining a histologic specimen is too difficult. In this evidence-based review, we address the importance of pleural fluid cytology in non-small cell lung cancer patients, from making the diagnosis to making treatment-related decisions when only pleural fluid is available.
AB - Lung cancer is the current leading cause of cancer-related deaths worldwide, and malignant pleural effusion, an indicator of the advanced stage of this disease, portends a poor prognosis. Thus, making an accurate diagnosis of malignant pleural effusion is of paramount importance. During the past decade, the prognosis of patients with advanced non-small cell lung cancer has improved substantially, especially in those treated with targeted therapy and immunotherapy. The use of pleural fluid cytology should not only provide diagnoses but also aid in the selection of targeted therapies, especially when obtaining a histologic specimen is too difficult. In this evidence-based review, we address the importance of pleural fluid cytology in non-small cell lung cancer patients, from making the diagnosis to making treatment-related decisions when only pleural fluid is available.
KW - actionable mutation
KW - cytology
KW - malignant pleural effusion
UR - http://www.scopus.com/inward/record.url?scp=85116520139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116520139&partnerID=8YFLogxK
U2 - 10.1097/LBR.0000000000000789
DO - 10.1097/LBR.0000000000000789
M3 - Review article
C2 - 34238837
AN - SCOPUS:85116520139
SN - 1944-6586
VL - 28
SP - 310
EP - 321
JO - Journal of Bronchology and Interventional Pulmonology
JF - Journal of Bronchology and Interventional Pulmonology
IS - 4
ER -